Inventor · disambiguated record
Laurent P. Debien
Also filed as: DEBIEN LAURENT · DEBIEN LAURENT P · DEBIEN LAURENT PIERRE PAUL
15 granted patents·5 pending applications·80 citations·filing 2017–2025
91Inventor score
Top patents by PatentIndex Score
20 records- 0198US11001603B2Modulators of 5′-nucleotidase, ecto and the use thereofARCUS BIOSCIENCES INC·Filed 2020·Granted May 11, 2021·13 cites·1 claims
- 0296US10239912B2Modulators of 5′-nucleotidase, ecto and the use thereofARCUS BIOSCIENCES INC·Filed 2017·Granted Mar 26, 2019·23 cites·47 claims
- 0395US11878965B2Inhibitors of peptidylarginine deiminasesGILEAD SCIENCES INC·Filed 2021·Granted Jan 23, 2024·4 cites·20 claims
- 0495US11667662B2Modulators of 5′-nucleotidase, ecto and the use thereofARCUS BIOSCIENCES INC·Filed 2021·Granted Jun 6, 2023·4 cites·9 claims
- 0595US10981944B2Modulators of 5′-nucleotidase, ecto and the use thereofARCUS BIOSCIENCES INC·Filed 2019·Granted Apr 20, 2021·11 cites·20 claims
- 0694US12168023B2Inhibitors of adenosine 5′-nucleotidaseARCUS BIOSCIENCES INC·Filed 2024·Granted Dec 17, 2024·1 cites·24 claims
- 0793US11976083B2Inhibitors of peptidylarginine deiminasesGILEAD SCIENCES INC·Filed 2021·Granted May 7, 2024·3 cites·15 claims
- 0892US10399962B2Azolopyrimidine for the treatment of cancer-related disordersARCUS BIOSCIENCES INC·Filed 2018·Granted Sep 3, 2019·13 cites·25 claims
- 0988US12195447B2Azolopyrimidine for the treatment of cancer-related disordersARCUS BIOSCIENCES INC·Filed 2021·Granted Jan 14, 2025·1 cites·2 claims
- 1087US11072597B2Azolopyrimidine for the treatment of cancer-related disordersARCUS BIOSCIENCES INC·Filed 2019·Granted Jul 27, 2021·3 cites·14 claims
- 1186US12459967B2Modulators of 5′-nucleotidase, ecto and the use thereofARCUS BIOSCIENCES INC·Filed 2023·Granted Nov 4, 2025·0 cites·11 claims
- 1285US11058704B2Inhibitors of adenosine 5′-nucleotidaseARCUS BIOSCIENCES INC·Filed 2017·Granted Jul 13, 2021·4 cites·25 claims
- 1383US2025319113A1Inhibitors of adenosine 5'-nucleotidaseARCUS BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 1473US12448388B2PRMT5 inhibitors and uses thereofGILEAD SCIENCES INC·Filed 2024·Granted Oct 21, 2025·0 cites·18 claims
- 1562US2025388585A1Prmt5 inhibitors and uses thereofGILEAD SCIENCES INC·Filed 2025·Application pending·0 cites
- 1660US2024254118A1Prmt5 inhibitors and uses thereofGILEAD SCIENCES INC·Filed 2023·Application pending·0 cites
- 1759US2025154172A1Prmt5 inhibitors and uses thereofGILEAD SCIENCES INC·Filed 2024·Application pending·0 cites
- 1858US12240862B2Inhibitors of peptidylarginine deiminasesGILEAD SCIENCES INC·Filed 2021·Granted Mar 4, 2025·0 cites·12 claims
- 1952US11931343B2CD73 inhibitorsARCUS BIOSCIENCES INC·Filed 2019·Granted Mar 19, 2024·0 cites·11 claims
- 2050US2025376484A1Prmt5 inhibitors and uses thereofGILEAD SCIENCES INC·Filed 2025·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Laurent P. Debien files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →